Clinical trials: Influenza Vaccines
Influenza
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine When Administered in Children Who Previously Participated in Study 115345
The purpose of this study is to assess the safety and immunogenicity of GSK Biologicals' investigational vaccine GSK2321138A in children who previously participated in study 115345 (FLU D-QIV-004 PRI) (NCT01439360).
- Trial name
- NCT01702454
- Testing
- Fluarix Quadrivalent
- Where
- 33 sites in Czechia, Poland and 2 more
- Volunteers
- 470 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
END STAGE RENAL DISEASE
A Pilot Study to Evaluate ZADAXIN's® (Thymalfasin) Ability to Enhance Immune Response to the H1N1sw Influenza Vaccine
The purpose of this explorative trial is to collect preliminary data on efficacy and safety of thymosin alpha 1 given at different doses as an adjuvant to egg-derived H1N1sw monovalent influenza vaccine in hemodialysis patients.
- Trial name
- NCT01031966
- Testing
- MF59 adjuvanted H1N1 influenza monovalent vaccine, Thymosin alpha 1
- Where
- Italy
- Volunteers
- 120 people
- Sponsor
- sigma-tau i.f.r. S.p.A.
Influenza
A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults
The purpose of this study is to evaluate humoral immunogenicity after 2 doses of mRNA-1018-H5, and to evaluate the safety and reactogenicity of mRNA-1018-H5 in adults ≥18 years of age.
- Trial name
- NCT07496450
- Testing
- mRNA-1018-H5
- Where
- 35 sites in United States, United Kingdom
- Volunteers
- 4,050 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine for the Elderly
The objective of the study is to evaluate immunogenicity between different formulations of GSK Biologicals' investigational vaccine GSK2186877A.
- Trial name
- NCT00938392
- Testing
- GSK investigational FluNG vaccine GSK2186877A, aged lot, GSK investigational FluNG vaccine GSK2186877A, fresh lot
- Where
- 6 sites in Estonia, Slovakia
- Volunteers
- 726 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and Adolescents
The present study is the first study designed to evaluate safety, tolerability and immunogenicity of the cell culture-derived influenza vaccine in healthy children and adolescents aged 3 to 17 years.
- Trial name
- NCT00645411
- Testing
- Cell culture-derived influenza subunit vaccine (cTIV), Egg derived influenza subunit vaccine (eTIV)
- Where
- 60 sites in United States, Croatia and 5 more
- Volunteers
- 3,604 people, healthy volunteers welcome
- Sponsor
- Novartis
Orthomyxoviridae Infection, Influenza
Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults
This study is designed to test lot consistency of three different manufacturing lots and to generate safety and immunogenicity data of the investigational vaccine administered via the ID route.
- Conditions
- Orthomyxoviridae Infection, Influenza, Myxovirus Infection
- Trial name
- NCT00772109
- Testing
- Influenza Virus Vaccine USP Trivalent Types A and B
- Where
- 49 sites in United States, Puerto Rico
- Volunteers
- 4,292 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Upper Respiratory Infection
Pilot Evaluation of CVT-E002 in Pediatric Upper Respiratory Tract Infection.
This is a randomized double-blind three-arm trial to evaluate two dosages of CVT-E002 against placebo in pediatric upper respiratory tract infections (URTI).
- Trial name
- NCT00255307
- Testing
- CVT-E002 ginseng extract
- Where
- 2 sites in Canada
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- CV Technologies
Influenza, Acute Upper Respiratory Infection
Treatment of Influenza in Routine Clinical Practice
This study evaluates the statistics of influenza and acute respiratory viral infections (ARVI) management in outpatient sites in Russia, Armenia, Moldova and Georgia (epidemiology: disease severity and bacterial exacerbations…
- Trial name
- FLU-EE (NCT02983019)
- Testing
- Kagocel
- Where
- 4 sites in Armenia, Georgia and 2 more
- Volunteers
- 18,946 people
- Sponsor
- Nearmedic Plus LLC
Influenza
Safety and Immunogenicity of Three Commercially Available Influenza Vaccines in Children Aged 6 to <36 Months
This phase IV protocol is designed to evaluate the safety, clinical tolerability and immunogenicity of the 2005-2006 formulation of three widely used conventional influenza vaccines in children aged 6 to 35 months
- Trial name
- NCT00311428
- Testing
- Influenza
- Where
- Finland
- Volunteers
- 270 people
- Sponsor
- Novartis
Influenza
Phase 1b Influenza Vaccine Study in Healthy Subjects
The purpose of this study is to see whether a single vaccination (injection) with the investigational influenza vaccine is safe in healthy subjects.
- Trial name
- NCT01181336
- Testing
- Influenza vaccine (FLU-v), FLU-v Control
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- PepTcell Limited
Bird Flu, Influenza
Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1
The purpose of this study is to compare the safety and immunogenicity over a 9-month period of five different dosages of Ad4-H5-Vtn in volunteers (Vaccinees) who receive three doses of the study vaccine or placebo.
- Trial name
- NCT01006798
- Testing
- Ad4-H5-Vtn, Sanofi Pasteur Influenza Virus Vaccine, H5N1
- Where
- 4 sites in United States
- Volunteers
- 166 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Virus Diseases, RNA Virus Infections
Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in Adults
A phase I/II trial conducted in a single centre, observer-blind, randomized, dose-ranging, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a single intramuscular injection of plant-based…
- Conditions
- Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
- Trial name
- NCT01991587
- Testing
- Low dose of quadrivalent VLP vaccine, Medium dose of quadrivalent VLP vaccine, High dose of quadrivalent VLP vaccine
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Medicago
Influenza
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVSQIV in Healthy Adults
This study aims to evaluate the safety and reactogenicity profile of CVSQIV at different dose levels.
- Trial name
- NCT05252338
- Testing
- CVSQIV
- Where
- 3 sites in Panama
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- CureVac
Influenza
Immunogenicity and Safety Study to Evaluate Different Formulations of GSK Biologicals' Influenza Vaccine GSK576389A
In order to find the formulation leading to a maximal increase of the immune response while maintaining an acceptable safety profile, this study is designed to evaluate the immunogenicity, safety and reactogenicity of the…
- Trial name
- NCT00540592
- Testing
- GlaxoSmithKline Biologicals' influenza vaccine GSK576389A, Fluarix
- Where
- 30 sites in Germany, Netherlands and 2 more
- Volunteers
- 2,007 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Syncytial Virus Infections
A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above
The purpose of this study is to assess the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when co-administered with the high dose quadrivalent influenza (FLU HD) vaccine in adults aged 65…
- Trial name
- NCT05559476
- Testing
- RSVPreF3 OA investigational vaccine, FLU HD vaccine
- Where
- 46 sites in United States
- Volunteers
- 1,029 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
This study is to evaluate the safety, tolerability and immune response when 13-valent pneumococcal conjugate vaccine (13vPnC) and the trivalent inactivated flu vaccine (TIV) are given together to healthy adults aged 50-59 years…
- Trial name
- NCT00521586
- Testing
- 13 valent pneumococcal conjugate vaccine
- Where
- 41 sites in United States
- Volunteers
- 1,116 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19, Influenza
Lot Consistency Study of COVID-19 and Influenza Combination Vaccine
The goal of Phase 3 Study is Comparing the Safety and Immune Response of Three Batches of a COVID-19 and Flu Combination Vaccine in Seniors Aged 65+
- Trial name
- CIC (NCT06482359)
- Testing
- coformulated CIC Vaccine, Fluzone HD trivalent
- Volunteers
- healthy volunteers welcome
- Sponsor
- Novavax
Influenza, Human
Prevalence, Strain Circulation and Disease Burden Study of Seasonal Influenza A and B in Panama, Selected Countries of Central America and the Caribbean From the Year 2010 to 2015
The purpose of this study is to assess the prevalence, strain circulation and disease burden of seasonal Influenza A and B in Panama, selected countries of Central America and the Caribbean from the Year 2010 to 2015.
- Trial name
- NCT02885246
- Testing
- Data collection
- Where
- Panama
- Volunteers
- 1,839 people
- Sponsor
- GlaxoSmithKline
Influenza
Safety, Tolerability, and Immunogenicity of GC3106 (Quadrivalent Cell-culture Based Influenza Vaccine)
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of GC3106 after single intramuscular administration in Korean healthy adults.
- Trial name
- NCT02249221
- Testing
- Quadrivalent cell-culture based influenza vaccin, Trivalent influenza vaccine
- Where
- South Korea
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Influenza
Evaluation of the Safety and Efficacy of a Monoclonal Antibody to Treat Influenza
The purpose of the study is to evaluate the efficacy and safety of MEDI8852 for the treatment of influenza caused by a wild type A/H1N1 challenge strain in healthy, influenza serosusceptible adults.
- Trial name
- NCT03903718
- Testing
- Oseltamivir, MEDI8852
- Volunteers
- healthy volunteers welcome
- Sponsor
- MedImmune LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.